ATTR

·MeSH: Amyloid Neuropathies

17 drugs in development·11 companies·1 clinical trial

Drug Pipeline by Phase

Approved(4)

Drug	Company
attruby	BridgeBio Pharma, Inc. (BBIO)
ONPATTRO	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
supplemental new drug	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Tegsedi	PTC THERAPEUTICS, INC. (PTCT)

Phase 3(8)

Drug	Company
akcea-ttr-lrx	AKCEA THERAPEUTICS, INC. (AKCA)
coramitug	PROTHENA CORP PUBLIC LTD CO (PRTA)
eplontersen	IONIS PHARMACEUTICALS INC (IONS)
eplontersen	ASTRAZENECA PLC (AZN)
nnc6019-0001	Novo Nordisk A/S (NVO)
NNC6019-0001	PROTHENA CORP PUBLIC LTD CO (PRTA)
Patisiran	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Vutrisiran	ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Phase 2(2)

Drug	Company
alxn2220	ASTRAZENECA PLC (AZN)
NNC6019	PROTHENA CORP PUBLIC LTD CO (PRTA)

Phase 1(1)

Drug	Company
NTLA-2001	Intellia Therapeutics, Inc. (NTLA)

Preclinical(2)

Drug	Company
ag10	Eidos Therapeutics, Inc. (EIDX)
ag10	ALEXION PHARMACEUTICALS, INC. (ALXN)

BioSniper tracks 17 drugs in development for ATTR across 11 companies.

There are 1 clinical trial targeting ATTR tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.